Red Light Therapy for Eyes: What the Research Shows for Vision and Eye Health

The relationship between red light and the eye is uniquely double-edged. On the one hand, an emerging body of research — most notably work from Glen Jeffery's lab at University College London — suggests that brief daily exposure to specific red wavelengths may improve photoreceptor function in aging eyes. On the other hand, conventional advice for red light therapy panels remains: protect your eyes. Both can be true at the same time, and the difference comes down to wavelength, dose, and intent.

The promising research: 670 nm and aging eyes

In a 2020 paper published in Journals of Gerontology, Jeffery and colleagues reported that brief (3-minute) daily exposure to deep red 670 nm light improved color contrast sensitivity in adults aged 40+ by an average of 17%. A 2024 follow-up in Nature Scientific Reports reported that even a single 3-minute exposure to 670 nm light early in the morning produced measurable improvements in cone-mediated color contrast that lasted up to a week.

The proposed mechanism is the same one driving red light therapy generally: 670 nm light is absorbed by mitochondria in the densely-packed photoreceptors of the retina, which are among the most metabolically demanding cells in the body. Aging photoreceptors lose mitochondrial efficiency; brief 670 nm exposure appears to support recovery of that efficiency.

Important caveats: the studies are small (typically dozens of participants), the outcomes are relatively narrow (color contrast sensitivity, not subjective vision quality), and there is currently no consumer device specifically validated for this protocol. Be cautious about marketing claims that promise vision restoration based on this research — the science is genuinely promising but early.

Macular degeneration and diabetic retinopathy

Photobiomodulation has been studied as an adjunct treatment for dry age-related macular degeneration (AMD), with the LIGHTSITE clinical trials being the most prominent example. LIGHTSITE III, a multicenter sham-controlled study published in 2024, reported small but measurable improvements in best-corrected visual acuity and contrast sensitivity in dry AMD patients treated with a combination of 590 nm, 660 nm, and 850 nm light over 13 months.

The relevant device (Valeda Light Delivery System) is a regulated medical device used under clinical supervision — it is not the same as a home red light panel and the protocols are precisely controlled. If you have diagnosed AMD, talk to a retinal specialist about whether PBM is appropriate; do not attempt to self-treat with consumer devices.

Eye strain and "screen fatigue"

Direct research on red light therapy for chronic digital eye strain is limited. Mechanistically, there's some rationale: prolonged near-vision work fatigues ciliary muscle and reduces blink rate, leading to mitochondrial-dependent inflammation in surface tissue. Brief red light exposure could support recovery. But this is hypothesis, not established practice. The well-established interventions for eye strain (the 20-20-20 rule, blinking exercises, blue light filtering, ergonomic adjustments) have far more evidence behind them.

Safety: when is red light unsafe for the eyes?

Red and NIR light are not UV — they don't damage DNA or cause sunburn. But high-irradiance light of any wavelength, sustained for long periods, can produce photochemical or thermal damage to the retina. The American Academy of Ophthalmology and most photobiomodulation practitioners recommend wearing the protective goggles included with consumer panels, particularly when using high-output devices at close range.

Key safety principles:

• Never stare directly into the LEDs of a high-power panel. Brief glances are safe; sustained gaze is not.
• Wear the included goggles when treating the face or upper body from close range with a high-irradiance panel.
• NIR (850 nm) is invisible. You can be exposing your eyes to substantial energy without realizing it. Eye protection matters most for NIR-heavy devices.
• The Jeffery 670 nm protocols use very low doses (a few minutes of low-intensity light) — they are not the same situation as standing 6 inches from a 1500-LED panel.
• If you have any retinal disease or use photosensitizing medications, talk to an ophthalmologist before starting any red light protocol.

Practical takeaways

• The emerging research on 670 nm for aging visual function is genuinely interesting, but no consumer device is currently validated for it. Don't chase it with off-label panel use.
• Macular degeneration treatment with photobiomodulation should be coordinated with a retinal specialist using regulated devices.
• For general red light therapy use (skin, recovery, joints), continue to wear the eye protection your panel comes with — particularly for NIR-heavy devices.
• Eye strain from screens is better addressed with proven ergonomic strategies than with experimental light protocols.

For more on protecting your eyes during normal red light therapy use, see our eye safety guide.

Selected references: Shinhmar et al., J Gerontol A Biol Sci Med Sci 2020 (670 nm and color contrast); Shinhmar et al., Sci Rep 2024 (single-exposure effects); Boyer et al., LIGHTSITE III, Retina 2024 (PBM for dry AMD).